Telcon RF Pharmaceutical
Key metrics
Earnings
| Revenue, Q3 2026 | ₩27.5bn |
|---|---|
| Revenue QoQ | -4.8% |
| Revenue YoY | +180.3% |
| Operating income, Q3 2026 | -₩3.0bn |
| Operating income QoQ | -276.3% |
| Operating income YoY | -34937.3% |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 5,329,916 shares |
| Potential new shares, last 12 months | 10,743,268 shares |
| Potential new shares, % of shares | 113.3% |
| Conversion price adjustments, last 12 months | 3 |
Supply contracts
| Supply contracts, last 12 months | ₩5.9bn |
|---|---|
| Supply contracts vs prior-year revenue | 13.6% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 4 |
|---|---|
| DART filings, previous 3 months | 20 |
Insider transactions
| Open-market buys, last 12 months (shares) | 0 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩0 |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 0 shares |
| Insiders who bought, last 12 months | 0 |
Insider transactions (last 12 months)
Open-market buys: 0 shares (₩0). Open-market sells: 0 shares (₩0). Net open-market buying: 0 shares. Insiders who bought: 0.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | Ebeokoeoinbeseuteumeonteuholdingseu Co., Ltd. (Controlling shareholder) | Other (Paid-in new shares) | +2,329,916 shares | — | — | |
| Jul 10, 2026 | NUON CO., LTD (Controlling shareholder) | Other (OTC sell) | -660,000 shares | — | — | |
| Jul 10, 2026 | Ebeokoeoinbeseuteumeonteuholdingseu Co., Ltd. (Controlling shareholder) | Other (OTC buy) | +660,000 shares | — | — | |
| Jun 6, 2026 | NUON CO., LTD (Controlling shareholder) | Other (Capital reduction) | -12,362,844 shares | — | — | |
| Apr 17, 2026 | NUON CO., LTD (Controlling shareholder) | Other (Paid-in new shares) | +3,000,000 shares | — | — |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩43.2bn | ₩719m |
| 2024 | ₩37.9bn | -₩71m |
| 2023 | ₩36.3bn | ₩965m |
Filing timeline
-
Telcon RF signs ₩3.6bn 5G small repeater supply contract
Telcon RF Pharmaceutical filed a supply contract for 5G small repeaters with Tjay Innovation worth ₩3.6bn, equal to 8.3% of revenue as reported. The contract period runs from Oct 23, 2026 to Mar 10, 2027.
-
Telcon RF signs ₩2.3bn wireless equipment supply contract with KT
Telcon RF Pharmaceutical filed a supply contract with KT Corp. for wireless equipment materials, with a contract amount of ₩2.3bn. The contract period runs from Oct 1, 2026 to Sep 30, 2027, and the filing reports it as 5.3% of revenue.